Ruhr-Universität Bochum (RUB)

Spectral fingerprints or spectral tilt? Evidence for distinct oscillatory signatures of memory formation (2019) Fellner MC, Gollwitzer S, Rampp S, Kreiselmeyr G, Bush D, Diehl B, Axmacher N, et al. Journal article Randomized phase 2 trial of chemoradiotherapy plus induction or consolidation chemotherapy as total neoadjuvant therapy for locally advanced rectal cancer: CAO/ARO/AIO-12 (2019) Hofheinz R, Fokas E, Allgaeuer M, Polat B, Klautke G, Grabenbauer G, Fietkau R, et al. Conference contribution Endovascular equipoise shift in a phase III randomized clinical trial of sonothrombolysis for acute ischemic stroke (2019) Alexandrov AV, Tsivgoulis G, Köhrmann M, Katsanos AH, Soinne L, Barreto AD, Rothlisberger T, et al. Journal article Development of a Model on Determinants of Malnutrition in Aged Persons: A MaNuEL Project (2019) Volkert D, Kiesswetter E, Cederholm T, Donini LM, Egiseer D, Norman K, Schneider SM, et al. Journal article EFFECTS OF THE GLUCAGON-LIKE PEPTIDE-1 (GLP-1) ANALOGUES SEMAGLUTIDE AND LIRAGLUTIDE ON RENAL OUTCOMES - A POOLED ANALYSIS OF THE SUSTAIN 6 AND LEADER TRIALS (2019) Perkovic V, Bain S, Bakris G, Buse J, Idorn T, Mahaffey K, Marso S, et al. Conference contribution EFFECTS OF SEMAGLUTIDE AND LIRAGLUTIDE ON URINARY ALBUMIN-TO-CREATININE RATIO (UACR) - A POOLED ANALYSIS OF SUSTAIN 6 AND LEADER (2019) Perkovic V, Bain S, Bakris G, Buse J, Idorn T, Mahaffey K, Marso S, et al. Conference contribution EGFR LOSS WITH GLUCAGON-LIKE PEPTIDE-1 (GLP-1) ANALOGUE TREATMENT: DATA FROM SUSTAIN 6 AND LEADER (2019) Perkovic V, Bain S, Bakris G, Buse J, Gondolf T, Idorn T, Lausvig N, et al. Conference contribution Characteristics in Non-Vitamin K Antagonist Oral Anticoagulant-Related Intracerebral Hemorrhage (2019) Gerner S, Kuramatsu J, Sembill J, Sprügel M, Hagen M, Knappe RU, Endres M, et al. Journal article Chemoradiotherapy plus induction versus consolidation chemotherapy as total neoadjuvant therapy for locally advanced rectal cancer: results of the German CAO/ARO/AIO-12 multicentre, open-label, randomised, phase 2 trial (2019) Fokas E, Allgaeuer M, Polat B, Klautke G, Grabenbauer G, Fietkau R, Kuhnt T, et al. Conference contribution Advantages and limitations of integrated flagellin adjuvants for HIV-based nanoparticle B-cell vaccines (2019) Barnowski C, Kadzioch N, Damm D, Yan H, Temchura V Journal article